{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:23:37Z","timestamp":1793053417468,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG062277"],"award-info":[{"award-number":["R01AG062277"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Renova"},{"DOI":"10.13039\/100009411","name":"Leonard D. Schaeffer Center for Health Policy and Economics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40258-020-00563-y","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T03:04:21Z","timestamp":1582513461000},"page":"669-677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2766-390X","authenticated-orcid":false,"given":"Jakub P.","family":"Hl\u00e1vka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soeren","family":"Mattke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asa","family":"Wilks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"issue":"3","key":"563_CR1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.7326\/M15-0406","volume":"163","author":"S Barua","year":"2015","unstructured":"Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. REstrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the united states. Ann Intern Med. 2015;163(3):215\u201323.","journal-title":"Ann Intern Med"},{"issue":"6","key":"563_CR2","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.cgh.2016.09.015","volume":"15","author":"J Chhatwal","year":"2017","unstructured":"Chhatwal J, He TH, Hur C, Lopez-Olivo MA. Direct-acting antiviral agents for patients with hepatitis C virus genotype 1 infection are cost-saving. Clin Gastroenterol Hepatol. 2017;15(6):827\u201337 (e8).","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"563_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2217\/cer-2017-0068","volume":"7","author":"G Hampson","year":"2018","unstructured":"Hampson G, Towse A, Pearson SD, Dreitlein WB, Henshall C. Gene therapy: evidence, value and affordability in the US health care system. J Comp Eff Res. 2018;7(1):15\u201328.","journal-title":"J Comp Eff Res"},{"key":"563_CR4","volume-title":"Borrowing for the cure: debt financing of breakthrough treatments","author":"S Mattke","year":"2015","unstructured":"Mattke S, Hoch E. Borrowing for the cure: debt financing of breakthrough treatments. Santa Monica: RAND Corporation; 2015 (PE-141-RC)."},{"issue":"3","key":"563_CR5","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jval.2017.12.013","volume":"21","author":"SK Schaffer","year":"2018","unstructured":"Schaffer SK, Messner D, Mestre-Ferrandiz J, Tambor E, Towse A. Paying for cures: perspectives on solutions to the \u201caffordability issue\u201d. Value Health. 2018;21(3):276\u20139.","journal-title":"Value Health."},{"key":"563_CR6","unstructured":"Gottlieb S, Carino T. Establishing new payment provisions for the high cost of curing disease. AEI Research. 2014. https:\/\/www.aei.org\/research-products\/report\/establishing-new-payment-provisions-for-the-high-cost-of-curing-disease\/. Accessed 1 Feb 2020."},{"issue":"2","key":"563_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.7326\/M18-0186","volume":"169","author":"N Sood","year":"2018","unstructured":"Sood N, Ung D, Shankar A, Strom BL. A novel strategy for increasing access to treatment for hepatitis C virus infection for medicaid beneficiaries. Ann Intern Med. 2018;169(2):118\u20139.","journal-title":"Ann Intern Med"},{"key":"563_CR8","unstructured":"Goldman D. What health care can learn from Netflix. LinkedIn; 2013."},{"key":"563_CR9","doi-asserted-by":"crossref","unstructured":"Hl\u00e1vka JP. Three essays in health economics: towards alternative payment models for high-value, high-cost medical treatments (Doctoral Dissertation, Pardee RAND Graduate School). 2018. https:\/\/www.rand.org\/pubs\/rgs_dissertations\/RGSD422.html. Accessed 1 Feb 2020.","DOI":"10.7249\/RGSD422"},{"issue":"12","key":"563_CR10","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","volume":"137","author":"EJ Benjamin","year":"2018","unstructured":"Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics\u20142018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67\u2013492.","journal-title":"Circulation."},{"issue":"1","key":"563_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jama.2013.7589","volume":"310","author":"AF Hernandez","year":"2013","unstructured":"Hernandez AF. Preventing heart failure. JAMA. 2013;310(1):44\u20135.","journal-title":"JAMA."},{"issue":"10","key":"563_CR12","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/mt.2015.158","volume":"23","author":"S Yl\u00e4-Herttuala","year":"2015","unstructured":"Yl\u00e4-Herttuala S. Gene therapy for heart failure: back to the bench. Mol Ther. 2015;23(10):1551\u20132.","journal-title":"Mol Ther"},{"key":"563_CR13","unstructured":"Renova Therapeutics. RT-100 (AC6 Gene Transfer). 2018. https:\/\/renovatherapeutics.com\/therapies\/rt-100-congestive-heart-failure\/. Accessed 1 Feb 2020."},{"issue":"3","key":"563_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/pop.2018.0103","volume":"22","author":"AC Dallmann","year":"2019","unstructured":"Dallmann AC, Wilks A, Mattke S. Impact of event severity on hospital rankings based on heart failure readmission rates. Popul Health Manag. 2019;22(3):243\u20137.","journal-title":"Popul Health Manag"},{"issue":"12","key":"563_CR15","first-page":"764","volume":"42","author":"T Kish","year":"2017","unstructured":"Kish T. New heart failure medications aim to fill significant gaps in treatment. Pharm Ther. 2017;42(12):764.","journal-title":"Pharm Ther"},{"key":"563_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/RMHP.S130341","volume":"10","author":"M Kilgore","year":"2017","unstructured":"Kilgore M, Patel HK, Kielhorn A, Maya JF, Sharma P. Economic burden of hospitalizations of Medicare beneficiaries with heart failure. Risk Manag Healthc Policy. 2017;10:63.","journal-title":"Risk Manag Healthc Policy"},{"issue":"11","key":"563_CR17","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"key":"563_CR18","unstructured":"Institute for Clinical and Economic Review. ICER Value Assessment Framework. Boston, MA; 2019. https:\/\/icer-review.org\/methodology\/icers-methods\/icer-value-assessment-framework-2\/. Accessed 1 Feb 2020."},{"issue":"12","key":"563_CR19","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1377\/hlthaff.2010.1147","volume":"30","author":"PJ Neumann","year":"2011","unstructured":"Neumann PJ, Chambers JD, Simon F, Meckley LM. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Aff. 2011;30(12):2329\u201337.","journal-title":"Health Aff"},{"key":"563_CR20","unstructured":"Centers for Medicare and Medicaid Services. CMS: Innovative treatments call for innovative payment models and arrangements. 2017. https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-innovative-treatments-call-innovative-payment-models-and-arrangements. Accessed 1 Feb 2020."},{"issue":"5 Suppl","key":"563_CR21","first-page":"s126","volume":"22","author":"S-L Chen","year":"2016","unstructured":"Chen S-L. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care. 2016;22(5 Suppl):s126\u201333.","journal-title":"Am J Manag Care."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-020-00563-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-020-00563-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-020-00563-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T01:06:38Z","timestamp":1614042398000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-020-00563-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["563"],"URL":"https:\/\/doi.org\/10.1007\/s40258-020-00563-y","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]},"assertion":[{"value":"24 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was partly funded by a fellowship from the University of Southern California, Leonard D. Schaeffer Center for Health Policy and Economics, by the National Institute on Aging of the National Institutes of Health under award number R01AG062277, and a contract from Renova Therapeutics to the RAND Corporation. Decisions on research design, interpretation of the findings, and submission were made by the authors; the sponsors did not have a role in any of these decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Mattke serves on the Board of Directors of Senscio Systems, Inc. and the scientific advisory board of AiCure Technologies, Boston Millennia Partners, and ZanoZano. He has received consulting fees from Biotronik, Bristol-Myers Squibb, and Defined Health. Jakub P. Hl\u00e1vka and Asa Wilks report no conflicts of interest. This article has been read and approved by all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}